iRadimed reports Q2 EPS 49c vs 42c last year

Reports Q2 revenue $20.4M vs $17.9M last year. “We are proud to report our sixteenth consecutive quarter of record revenue, reaching $20.4 million in the second quarter of 2025, a 14% increase year-over-year. Our GAAP diluted EPS of $0.45, up 18% year-over-year and an increase of 22% from the first quarter of 2025, which exceeds our guidance and reflects our relentless focus on operational excellence. Our gross profit margin for the quarter was 78%, driven in part by increased overhead absorption as we ramped up finished goods inventory ahead of our move to our new facility on July 7, 2025. We have a record backlog for our pump and monitor products as of June 30, 2025, which underscores unprecedented market demand, and reinforces our growth trajectory. While we anticipate some operational inefficiencies in the third quarter of 2025 as we settle into our new facility, which may moderate our EPS growth, we believe that our expanded capacity and the commercialization of our next-generation MRI-compatible IV infusion pump, beginning in late 2025 and accelerating in early 2026, will help drive sustained growth and deliver long-term stockholder value,” said Roger Susi, President and Chief Executive Officer of Iradimed (IRMD).